WallStreetZenWallStreetZen

NASDAQ: BIOA
Bioage Labs Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BIOA

Based on 5 analysts offering 12 month price targets for Bioage Labs Inc

Min Forecast
$12.00-26.15%
Avg Forecast
$51.80+218.77%
Max Forecast
$73.00+349.23%

Should I buy or sell BIOA stock?

Based on 5 analysts offering ratings for Bioage Labs Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
1 analysts 20%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BIOA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BIOA as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their BIOA stock forecasts and price targets.

BIOA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-10Find Out Why
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-18Find Out Why
lockedlocked$00.00+00.00%2026-01-27
lockedlocked$00.00+00.00%2025-12-08

1 of 1

Forecast return on equity

Is BIOA forecast to generate an efficient return?

Company
-69.05%
Industry
58.96%
Market
179.06%
BIOA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIOA forecast to generate an efficient return on assets?

Company
-63.71%
Industry
19.3%
BIOA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIOA earnings per share forecast

What is BIOA's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$2.76
Avg 2 year Forecast
-$2.75
Avg 3 year Forecast
-$4.23

BIOA revenue forecast

What is BIOA's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$72.5M+705.55%
Avg 2 year Forecast
$695.6k-92.27%
Avg 3 year Forecast
$0.0-100%

BIOA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
BIOA$16.25$51.80+218.77%Strong Buy
ESPR$2.85$6.33+122.21%Strong Buy
TLRY$6.54$10.00+52.91%Hold
ETON$23.45$39.33+67.73%Strong Buy
EVO$2.46N/AN/A
View Top Pharmaceutical Stocks

Bioage Labs Stock Forecast FAQ

Is Bioage Labs Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: BIOA) stock is to Strong Buy BIOA stock.

Out of 5 analysts, 3 (60%) are recommending BIOA as a Strong Buy, 1 (20%) are recommending BIOA as a Buy, 1 (20%) are recommending BIOA as a Hold, 0 (0%) are recommending BIOA as a Sell, and 0 (0%) are recommending BIOA as a Strong Sell.

If you're new to stock investing, here's how to buy Bioage Labs stock.

What is BIOA's earnings growth forecast for 2026-2029?

(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 13.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.

Bioage Labs's earnings in 2026 is -$80,605,000.On average, 9 Wall Street analysts forecast BIOA's earnings for 2026 to be -$122,448,177, with the lowest BIOA earnings forecast at -$137,870,141, and the highest BIOA earnings forecast at -$97,391,368. On average, 9 Wall Street analysts forecast BIOA's earnings for 2027 to be -$121,920,057, with the lowest BIOA earnings forecast at -$144,828,886, and the highest BIOA earnings forecast at -$78,285,884.

In 2029, BIOA is forecast to generate -$187,859,494 in earnings, with the lowest earnings forecast at -$191,365,495 and the highest earnings forecast at -$181,735,089.

What is BIOA's revenue growth forecast for 2026-2028?

(NASDAQ: BIOA) Bioage Labs's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.19%.

Bioage Labs's revenue in 2026 is $8,995,000.On average, 9 Wall Street analysts forecast BIOA's revenue for 2026 to be $3,215,712,523, with the lowest BIOA revenue forecast at $0, and the highest BIOA revenue forecast at $22,134,401,809. On average, 9 Wall Street analysts forecast BIOA's revenue for 2027 to be $30,872,331, with the lowest BIOA revenue forecast at -$83,852,881, and the highest BIOA revenue forecast at $232,993,703.

In 2028, BIOA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BIOA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BIOA) forecast ROA is -63.71%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 19.3%.

What is BIOA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year BIOA price target, the average BIOA price target is $51.80, with the highest BIOA stock price forecast at $73.00 and the lowest BIOA stock price forecast at $12.00.

On average, Wall Street analysts predict that Bioage Labs's share price could reach $51.80 by Mar 10, 2027. The average Bioage Labs stock price prediction forecasts a potential upside of 218.77% from the current BIOA share price of $16.25.

What is BIOA's Earnings Per Share (EPS) forecast for 2026-2029?

(NASDAQ: BIOA) Bioage Labs's current Earnings Per Share (EPS) is -$2.24. On average, analysts forecast that BIOA's EPS will be -$2.76 for 2026, with the lowest EPS forecast at -$3.11, and the highest EPS forecast at -$2.19. On average, analysts forecast that BIOA's EPS will be -$2.75 for 2027, with the lowest EPS forecast at -$3.26, and the highest EPS forecast at -$1.76. In 2029, BIOA's EPS is forecast to hit -$4.23 (min: -$4.31, max: -$4.10).

What is BIOA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BIOA) forecast ROE is -69.05%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.